Raymond James Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.13M Sell
22,408
-35,661
-61% -$3.81M ﹤0.01% 3469
2026
Q2
$6.45M Buy
58,069
+8,149
+16% +$737K ﹤0.01% 2542
2026
Q1
$4.34M Buy
49,920
+8,805
+21% +$856K ﹤0.01% 2707
2025
Q4
$4.4M Sell
41,115
-2,978
-7% -$316K ﹤0.01% 2623
2025
Q3
$4.45M Buy
44,093
+33,547
+318% +$3.11M ﹤0.01% 2537
2025
Q2
$666K Buy
+10,546
New +$646K ﹤0.01% 3829
2025
Q1
– Sell
-3,892
Closed -$218K – 4932
2024
Q4
$218K Buy
+3,892
New +$215K ﹤0.01% 4363

Other funds holding RYTM

Raymond James Financial's RYTM Position: Q3 2026 in Review

Raymond James Financial reduced its Rhythm Pharmaceuticals (RYTM) stake by 61% in Q3 2026, selling an estimated $3.81M and leaving 22,408 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Raymond James Financial first reported a position in RYTM in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.45M in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Raymond James Financial held 22,408 shares of Rhythm Pharmaceuticals worth $2.13M as of Q3 2026.
  • Raymond James Financial sold 35,661 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $3.81M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3469 holding.
  • Raymond James Financial first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Rhythm Pharmaceuticals position peaked at $6.45M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.